NO963589L - Beskrivelse av kreftilstander ved MAGE-genuttrykking - Google Patents

Beskrivelse av kreftilstander ved MAGE-genuttrykking

Info

Publication number
NO963589L
NO963589L NO963589A NO963589A NO963589L NO 963589 L NO963589 L NO 963589L NO 963589 A NO963589 A NO 963589A NO 963589 A NO963589 A NO 963589A NO 963589 L NO963589 L NO 963589L
Authority
NO
Norway
Prior art keywords
description
gene expression
mage gene
cancer states
mage
Prior art date
Application number
NO963589A
Other languages
English (en)
Other versions
NO963589D0 (no
Inventor
Etienne De Plaen
Thierry Boon-Falleur
Bernard Lethe
Jean-Pierre Szikora
Charles De Smet
Patrick Chomez
Beatrice Gaugler
Benoit Van Den Eynde
Francis Brasseur
Jean-Jacques Patard
P Weynants
M Marchand
Pierre Van Der Bruggen
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/204,727 external-priority patent/US5512437A/en
Priority claimed from US08/209,172 external-priority patent/US5763165A/en
Priority claimed from US08/299,849 external-priority patent/US5612201A/en
Priority claimed from US08/346,774 external-priority patent/US5512444A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO963589D0 publication Critical patent/NO963589D0/no
Publication of NO963589L publication Critical patent/NO963589L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det beskrives en fremgangsmåte for å bestemme kreft- tilstander. Fremgangsmåten involverer å analysere for uttrykking av et gen som koder for i det minste ett MAGE- tumorrejeksjonsantigen eller dets forløper-ekspresjons- produkt.
NO963589A 1994-03-01 1996-08-28 Beskrivelse av kreftilstander ved MAGE-genuttrykking NO963589L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/204,727 US5512437A (en) 1994-03-01 1994-03-01 Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US08/209,172 US5763165A (en) 1994-03-10 1994-03-10 Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US08/299,849 US5612201A (en) 1991-05-23 1994-09-01 Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
US08/346,774 US5512444A (en) 1994-03-01 1994-11-30 Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
PCT/US1995/002203 WO1995023874A1 (en) 1994-03-01 1995-02-23 Determination of cancerous conditions by mage gene expression

Publications (2)

Publication Number Publication Date
NO963589D0 NO963589D0 (no) 1996-08-28
NO963589L true NO963589L (no) 1996-10-31

Family

ID=27498545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963589A NO963589L (no) 1994-03-01 1996-08-28 Beskrivelse av kreftilstander ved MAGE-genuttrykking

Country Status (11)

Country Link
EP (1) EP0871765B1 (no)
JP (1) JPH09509832A (no)
KR (1) KR100316209B1 (no)
AT (1) ATE209690T1 (no)
AU (1) AU698310B2 (no)
CA (1) CA2184482A1 (no)
DE (1) DE69524264T2 (no)
FI (1) FI963393A0 (no)
NO (1) NO963589L (no)
NZ (1) NZ282536A (no)
WO (1) WO1995023874A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221593B1 (en) * 1996-10-03 2001-04-24 Ludwig Institute For Cancer Research Method for determining cancer by determining expression of MAGE-10
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
WO1998046788A2 (en) 1997-04-11 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Primers and methods for the detection of disseminated tumor cells
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
JP2001516009A (ja) * 1997-07-17 2001-09-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ガン関連核酸及びポリペプチド
CZ298347B6 (cs) 1998-02-05 2007-09-05 Glaxosmithkline Biologicals S.A. Fúzní protein z rodiny MAGE, kódová sekvence nukleové kyseliny, vektor, hostitelská bunka, vakcina a použití fúzního proteinu pro výrobu vakciny
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
CA2340592A1 (en) 1998-08-31 2000-03-09 Urogenesys, Inc. Phelix: a testis-specific protein expressed in cancer
US6733998B1 (en) * 1998-12-07 2004-05-11 Sloan-Kettering Institute For Cancer Research Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
US6475794B1 (en) * 1999-10-08 2002-11-05 The Johns Hopkins University Converting diploidy to haploidy for genetic diagnosis
US7393657B2 (en) 2001-04-12 2008-07-01 Imperial College Innovations Limited Diagnosis and treatment of cancer: I
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
DK3565828T3 (da) 2017-01-05 2022-02-21 Kahr Medical Ltd Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
JP2021515588A (ja) 2018-01-26 2021-06-24 ケンブリッジ エンタープライズ リミティッド ペプチド交換蛋白質
EP3814385A4 (en) 2018-07-11 2022-04-06 KAHR Medical Ltd. SIRPALPHA-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020041662A1 (en) 2018-08-24 2020-02-27 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
WO2021005599A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Also Published As

Publication number Publication date
DE69524264T2 (de) 2002-07-18
JPH09509832A (ja) 1997-10-07
FI963393A (fi) 1996-08-30
EP0871765B1 (en) 2001-11-28
KR970701790A (ko) 1997-04-12
ATE209690T1 (de) 2001-12-15
WO1995023874A1 (en) 1995-09-08
FI963393A0 (fi) 1996-08-30
AU1968295A (en) 1995-09-18
EP0871765A1 (en) 1998-10-21
DE69524264D1 (de) 2002-01-10
KR100316209B1 (ko) 2002-06-26
CA2184482A1 (en) 1995-09-08
NZ282536A (en) 1998-07-28
AU698310B2 (en) 1998-10-29
EP0871765A4 (en) 1999-08-11
NO963589D0 (no) 1996-08-28

Similar Documents

Publication Publication Date Title
NO963589D0 (no) Beskrivelse av kreftilstander ved MAGE-genuttrykking
ATE258379T1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
DE3574730D1 (de) Monoklonaler antikoerper gegen ein humanes tumor-karzinom-assoziiertes antigen.
AU588542B2 (en) Immunoassay for breast cancer employing monoclonal antibodies
DE69535002D1 (de) Rekombinante humanisierte antikörper gegen fb5
NO902696D0 (no) Ny familie av modifiserte hoeyaffinitetsantistoff for kreftbehandling.
NO821367L (no) Fremgangsmaate ved fremstilling av slitebestandige, sammensatte materialer.
HK1008228A1 (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
NO892068D0 (no) Fremgangsmaate ved fremstilling av naftatiozepinoner.
DE69004300D1 (de) Verfahren zur Herstellung wellenförmiger Imbiss-Chips.
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
IT1226719B (it) Metodo per produrre fluororesina tenera polimerizzata ad innesto.
DE59005545D1 (de) Verwendung von hydroxymischethern als hilfsmittel für die feststoffentwässerung.
WO1996029409A3 (en) Rage tumor rejection antigens
FR2714915B1 (fr) Fragment de gène, etc, d'un anticorps reconnaissant une mucine spécifique de cancers .
AU5246190A (en) Retinoblastoma gene product antibodies and uses therefor
FI961723A (fi) Uusi eturauhas/paksunsuolikasvaimen suppressorigeeni
IT8420766A0 (it) Macchina per la realizzazione, da tondelli metallici, di anelli esterni per monete o medaglie bimetalliche.
EP1072272A4 (en) METHOD FOR PRODUCING A SPECIFIC ANTISERUM AGAINST ANTI-GENERAL TUMOR AND METHOD FOR DIAGNOSIS OF VICTORY TUMORS THAT USES THIS
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
FR2720466B1 (fr) Procédé pour la fabrication d'une garniture plate imprégnée.
TR199501210A2 (tr) Deri yaglama maddelerinin üretilmesine mahsus usul.
NO891898D0 (no) Fremgangsmaate ved fremstilling av naftotiazepinoner.
EP0185135A3 (en) Novel monoclonal antibody

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application